Novo Nordisk Reports Insider Share Transactions
Ticker: NONOF · Form: 6-K · Filed: Nov 19, 2024 · CIK: 353278
Sentiment: neutral
Topics: insider-trading, disclosure, regulatory-filing
Related Tickers: NVO
TL;DR
Novo Nordisk execs and board members bought/sold shares, filing shows.
AI Summary
Novo Nordisk A/S filed a Form 6-K on November 19, 2024, to report transactions in its shares by board members, executives, and associated persons. This disclosure is in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Why It Matters
This filing provides transparency into the trading activities of key individuals within Novo Nordisk, which can offer insights into their confidence in the company's future performance.
Risk Assessment
Risk Level: low — This is a routine disclosure of insider trading activity, not a material event impacting the company's operations or financial health.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant
- Regulation No. 596/2014 (regulation) — Governing market abuse disclosures
FAQ
What type of transactions are being disclosed by Novo Nordisk?
The filing discloses transactions in Novo Nordisk shares made by the company's board members, executives, and their associated persons.
What regulation governs these disclosures?
These disclosures are made in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
When was this report filed with the SEC?
The report was filed on November 19, 2024.
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report transactions in Novo Nordisk shares by company insiders and associated persons.
Where is Novo Nordisk A/S headquartered?
Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 13.3 · Accepted 2024-11-19 09:24:12
Filing Documents
- f6k_111924.htm (6-K) — 28KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-24-006444.txt ( ) — 167KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: November 19, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer